Healthcare Industry News: sanofi-aventis
News Release - September 26, 2007
Paramount BioSciences Appoints Business Development Vice PresidentNEW YORK, Sept. 26, 2007 (Healthcare Sales & Marketing Network) -- Paramount BioSciences, a global pharmaceutical development and healthcare investment firm, announced today that Robert Jacks has joined the Company as Vice President of Business Development, located in its New York office. Mr. Jacks will seek, evaluate and in-license drug candidates and technologies for companies founded or supported by Paramount BioSciences.
``We are delighted to welcome Robert Jacks to the Paramount BioSciences' team,'' said Bertrand Liang, MD, Vice Chairman of Paramount BioSciences. ``Mr. Jacks' significant experience in business development and new product development will bring enormous value to the company as we work with our portfolio companies to grow their product pipelines across a broad range of therapeutic areas.''
Prior to joining Paramount BioSciences, Mr. Jacks held various management positions at Pfizer Inc in Corporate Finance, New Product Development, and Business Development from 2001 to 2007. While at Pfizer, Mr. Jacks was instrumental in several high profile transactions including the 2006 acquisition of PowderMed, the 2005 acquisition of Vicuron, the 2005 in-license of the TLR9 agonist PF-3512676 from Coley, the 2004 acquisition of European rights to Campto from sanofi-aventis, and the 2003 in-license of the fluoroquinolone DK-507k from Daiichi. Mr. Jacks also guided the development of several late-stage internal products including Selzentry(tm), the recently approved, first-in-class CCR5 antagonist for HIV; CP-675206, the CTLA-4 monoclonal antibody in phase III development for melanoma; and UK-453061, the NNRTI in phase II development for HIV. Prior to joining Pfizer, Mr. Jacks worked as a Project Manager and Project Engineer for a private engineering and construction company located in Birmingham, AL.
Mr. Jacks holds a B.S. in Civil Engineering from Duke University, an M.S. in Civil Engineering from Stanford University, and an M.B.A. in Finance from Columbia University.
``I am excited to join the Paramount BioSciences' team and work with its portfolio of biotechnology companies,'' said Mr. Jacks. ``Paramount's innovative model and unique capabilities offer significant advantages to licensing partners. As a result, Paramount is well positioned to capitalize on the tremendous opportunities in the biopharmaceutical industry.''
About Paramount BioSciences, LLC
Paramount BioSciences, LLC is a global pharmaceutical development and healthcare investment firm that conceives, nurtures, and supports new biotechnology companies. For additional information about Paramount BioSciences, please visit http://www.paramountbio.com.
Source: Paramount BioSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.